Posted on 04/06/2025 9:16:37 AM PDT by ConservativeMind
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research.
In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and HFpEF.
HFpEF occurs when the heart muscle cannot enlarge sufficiently to accommodate the blood it receives, causing pressure in the heart to become elevated. Chronic kidney disease occurs when the kidneys do not filter waste from the blood as they should, leading to a buildup of toxins.
Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and kidney health.
The SUMMIT trial enrolled 731 patients with HFpEF and a body mass index of 30 m2/kg or higher.
At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure compared with the placebo group. Participants taking tirzepatide also had a better average Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) than the placebo group, showing a significant improvement in terms of the study's second primary endpoint, a measure of heart failure severity.
For both of these primary endpoints, researchers observed similar improvement with tirzepatide in patients with and without chronic kidney disease. Overall, participants with chronic kidney disease faced poorer outcomes across multiple metrics compared to participants without chronic kidney disease.
The researchers used two strategies for assessing kidney function, measuring creatinine and cystatin C at 12, 24 and 52 weeks. Ultimately, participants taking tirzepatide showed significant improvements over those taking placebo in terms of both markers of kidney function, although the results showed different patterns over time and among different patient groups.
(Excerpt) Read more at medicalxpress.com ...
.
Tirzepatide is sold under the brand name Mounjaro for diabetes treatment and Zepbound for weight loss and treatment of obstructive sleep apnea. It is not a new GPD1 and is used by many already. But it has some side effects that can be serious.
Inflammation of the pancreas (pancreatitis).
Low blood sugar (hypoglycemia)
Kidney problems (kidney failure).
Severe stomach problems
Possible anapo
The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. So it has it’s drawbacks and dangers. And anaphylaxis has been a problem
wy69
Has anyone thought about not eating so much, or taking in so many calories?
Hmm... If you suffer from obesity, kidney disease and heart failure... Maybe you should be looking for a plot and a coffin, and not a pill.
“Has anyone thought about not eating so much, or taking in so many calories?”
Now you’re just meddling.
Not eating “so much” of what? How much is “so much?”
Of that which makes you so fat. In addition, it is Nutrition 100 that if one takes in more calories than one burns up, then one is going to get fat.
Couple the injection of too many calories and no sweat expiration, the result is accumulation of fat.
What do you mean ‘of that which makes you fat?’ Specifically. Of what you eat, what makes you fat, and what doesn’t? Since you made the distinction, please let us know.
You are supposed to eat in moderation. If you don’t and don’t do anything except sit on your a@@, you will get fat. You post insipid arguments.
Now it’s obvious that you don’t know what you’re talking about when you tell people to eat less of that which makes them fat.
Eat less of what—exactly. You don’t know.
But, I would suggest you spend some time in a grocery store and observe what ample people put into their carts when checking out.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.